# A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

> **NCT06321523** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 13 (actual)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy

## Interventions

- **DRUG:** Tafamidis 61 milligrams

## Key facts

- **NCT ID:** NCT06321523
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-19
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-13
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06321523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06321523, "A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06321523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*